NCT03084133

Brief Summary

The relative risk of colorectal cancer (CRC) is increased in first-degree relatives of patients with CRC or advanced adenoma. In the high-risk CCR population defined by a family history at the first stage of CRC or advanced adenoma before age 60, total colonoscopy is the recommended screening test. In France, the rate of screening colonoscopy in this population at high risk of CRC is insufficient, which limits the effectiveness of this targeted screening. The main reason for this low participation rate is that most patients undergoing RCC or advanced adenoma are unaware of the family implications of their diagnosis and therefore reluctant to disseminate this information to their patients Related matters. The need for a better perception of the personal risk of CRC in first-degree relatives of patients with CRC or advanced adenoma, with the expected coronary adherence to increasing screening, requires a good understanding of risk through Clear, adapted and comprehensible information that can be relayed personally by the case-index. The objective of this project is to develop a personalized prevention and screening program for the JRC in order to meet the needs of the relatives of the sick. The means of intervention that will be implemented respond to the need to better take into account the level of CRC risk in a family-based CRC screening and prevention approach adapted to a high-risk CRC group characterized by Family history at the first stage of CRC or advanced adenoma and, consequently, to improve the information of the subjects concerned by screening and prevention of CRC. The aim of the case-index education is to induce its intervention with its relatives to promote CCR screening. The use of the index case, as a means of providing information to relatives, implies an educational and psychological approach, based on evidence, but adapted and personalized.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2017

Typical duration for not_applicable

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 28, 2017

Completed
20 days until next milestone

First Posted

Study publicly available on registry

March 20, 2017

Completed
21 days until next milestone

Study Start

First participant enrolled

April 10, 2017

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 19, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 19, 2019

Completed
Last Updated

September 26, 2019

Status Verified

September 1, 2019

Enrollment Period

1.8 years

First QC Date

February 28, 2017

Last Update Submit

September 25, 2019

Conditions

Keywords

Therapeutic education strategy

Outcome Measures

Primary Outcomes (1)

  • Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.

    Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.

    12 MONTHS

Secondary Outcomes (10)

  • Psychological determinants (quality of relationship with relatives, motivation to inform relatives) that can condition the enrollment in the education program.

    12 MONTHS

  • Social and demographic factors in index cases associated with screening colonoscopy in related subjects: age, sex, educational level, socio-professional category.

    12 MONTHS

  • Social and demographic factors associated with screening colonoscopy in related subjects: age, sex, educational level, socio-professional category.

    12 MONTHS

  • How to access screening colonoscopy: pathway (public or private), direct access to the gastroenterologist or through the attending physician.

    12 MONTHS

  • Time to access the colonoscopy (time between the procedure and the completion of the screening colonoscopy).

    2 MONTHS

  • +5 more secondary outcomes

Study Arms (2)

Therapeutic Education Strategy

EXPERIMENTAL

Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account. Intervention 'Therapeutic Education Strategy'

Behavioral: Therapeutic Education Strategy

Control group

NO INTERVENTION

Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice

Interventions

In the experimental arm of the study ("intervention group"), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the "intention" of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a "competence" approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002).

Therapeutic Education Strategy

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Index case:
  • Patients with colorectal adenocarcinoma or advanced adenoma diagnosed (definition of advanced adenoma (Winawer, 2006): adenoma of diameter ≥ 10 mm and / or severe dysplasia and / or with a villous contingent).
  • Patients with at least one relative of the first degree belonging to the target population of the screening strategy evaluated (between 40 and 75 years of age and less than 10 years of age of the case-index) and residing in France.
  • Affiliation of the patient to a social security scheme (including CMU).
  • Understanding of the French language.
  • Related:
  • They correspond to the target population at high risk of colorectal cancer targeted by this program of promotion of colonoscopy screening:
  • Subjects related to 1st degree to the index case and in contact with it.
  • Age between 40 and 75 years of age or less than 10 years of age of the index case.
  • Resides in France

You may not qualify if:

  • Index case :
  • Chronic inflammatory bowel disease.
  • Genetic predisposition syndrome identified with colorectal cancer (Lynch syndrome, familial polyposis linked to the APC and MYH genes).
  • Patient's knowledge of a first-degree relative with colorectal adenocarcinoma or advanced adenoma.
  • Isolated patient of his / her first-degree relatives and not wishing to re-establish contact with them.
  • Advanced colorectal cancer with a life expectancy \<6 months and / or a WHO ≥ 2 general condition.
  • Transmission of information to the family already carried out.
  • Related :
  • \- Not applicable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Service d'Hépatogastro-entérologie CHU ANGERS

Angers, France

Location

Service d'Hépatogastro-entérologie CHG BLOIS

Blois, 41 000, France

Location

Service d'Hépatogastro-entérologie CHG de DREUX

Dreux, France

Location

Service de Médecine CHG de Loches

Loches, France

Location

Service d'Hépatogastro-entérologie CHU de NANTES

Nantes, France

Location

Service d'Hépatogastro-entérologie CHR d'Orléans

Orléans, 45067, France

Location

Service d'Hépatogastro-entérologie CHU POITIERS

Poitiers, 86 000, France

Location

Service d'Hépatogastro-entérologie CHRU de TOURS

Tours, 37044, France

Location

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Study Officials

  • CAROLI BOSC Françis- Xavier, Pr

    University Hospital, Angers

    PRINCIPAL INVESTIGATOR
  • MATYSIAK-BUDNIK Tamara, Pr

    Nantes University Hospital

    PRINCIPAL INVESTIGATOR
  • LANDAU Alain, Dr

    CHG DREUX

    PRINCIPAL INVESTIGATOR
  • GARGOT Denis, Dr

    CHG BLOIS

    PRINCIPAL INVESTIGATOR
  • BARBIEUX Jean- Pierre, Dr

    CHG LOCHES

    PRINCIPAL INVESTIGATOR
  • TOUGERON David, Pr

    CHU Poitiers

    PRINCIPAL INVESTIGATOR
  • LEGOUX Jean- Louis, Dr

    CHR ORLEANS

    PRINCIPAL INVESTIGATOR
  • BOURGEOIS Hugues, Dr

    Clinic Victor Hugo LE MANS

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: "Intervention group" means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account. "Control group": provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the case-index according to its usual practice and adapted to the level of understanding of Case-index.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2017

First Posted

March 20, 2017

Study Start

April 10, 2017

Primary Completion

January 19, 2019

Study Completion

January 19, 2019

Last Updated

September 26, 2019

Record last verified: 2019-09

Locations